Total Payments
$78,788
2023 Payments
$5,358
Companies
4
Transactions
75
Medicare Patients
113
Medicare Billing
$13,110
Payment Breakdown by Category
Consulting$64,621 (82.0%)
Other$5,798 (7.4%)
Travel$5,728 (7.3%)
Research$1,249 (1.6%)
Food & Beverage$1,228 (1.6%)
Education$163.33 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,621 | 15 | 82.0% |
| Travel and Lodging | $5,728 | 13 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,298 | 5 | 5.5% |
| Honoraria | $1,500 | 1 | 1.9% |
| Unspecified | $1,249 | 9 | 1.6% |
| Food and Beverage | $1,228 | 25 | 1.6% |
| Education | $163.33 | 7 | 0.2% |
Payments by Type
General
$77,538
66 transactions
Research
$1,249
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $53,119 | 43 | $0 (2023) |
| ViiV Healthcare Company | $23,550 | 22 | $0 (2023) |
| Theratechnologies Inc. | $2,064 | 5 | $0 (2018) |
| Merck Sharp & Dohme LLC | $54.25 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,358 | 3 | ViiV Healthcare Company ($5,319) |
| 2022 | $3,954 | 6 | ViiV Healthcare Company ($3,900) |
| 2021 | $7,050 | 5 | ViiV Healthcare Company ($5,160) |
| 2020 | $13,988 | 3 | Gilead Sciences, Inc. ($10,308) |
| 2019 | $31,132 | 22 | Gilead Sciences, Inc. ($25,641) |
| 2018 | $6,227 | 18 | Gilead Sciences, Inc. ($4,163) |
| 2017 | $11,078 | 18 | Gilead Sciences Inc ($11,078) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: HIV | ||||||
| 02/22/2023 | ViiV Healthcare Company | CABENUVA (Biological), APRETUDE, TIVICAY | Food and Beverage | In-kind items and services | $118.57 | General |
| Category: HIV | ||||||
| 02/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $39.69 | General |
| 09/29/2022 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $10.85 | General |
| 09/28/2022 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $10.85 | General |
| 09/28/2022 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $10.85 | General |
| 09/28/2022 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $10.85 | General |
| 09/28/2022 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $10.85 | General |
| 03/29/2022 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 07/27/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: HIV | ||||||
| 06/08/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: HIV | ||||||
| 04/27/2021 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: HIV | ||||||
| 03/03/2021 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $840.00 | General |
| Category: COVID-19 | ||||||
| 02/23/2021 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: COVID-19 | ||||||
| 12/31/2020 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,468.49 | General |
| 10/13/2020 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 05/08/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,680.00 | General |
| 12/31/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $16,182.57 | General |
| 12/31/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,217.65 | General |
| 11/19/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $137.42 | General |
| 11/06/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,970.00 | General |
| 10/26/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $44.64 | General |
| 10/26/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $44.20 | General |
| 10/26/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $44.19 | General |
| 06/06/2019 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $108.54 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ViiV Healthcare Company | $1,249 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 43 | 72 | $22,223 | $5,436 |
| 2022 | 1 | 14 | 29 | $7,598 | $1,863 |
| 2021 | 2 | 29 | 47 | $12,029 | $3,010 |
| 2020 | 2 | 27 | 50 | $12,770 | $2,801 |
Total Patients
113
Total Services
198
Medicare Billing
$13,110
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 32 | $7,904 | $2,183 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 29 | $7,598 | $1,711 | 22.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $6,721 | $1,542 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 29 | $7,598 | $1,863 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 28 | $7,336 | $1,815 | 24.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 19 | $4,693 | $1,195 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 22 | $5,434 | $1,403 | 25.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 16 | 28 | $7,336 | $1,398 | 19.1% |
About Dr. Shobha Swaminathan, M.D
Dr. Shobha Swaminathan, M.D is a Infectious Disease healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275564411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shobha Swaminathan, M.D has received a total of $78,788 in payments from pharmaceutical and medical device companies, with $5,358 received in 2023. These payments were reported across 75 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($64,621).
As a Medicare-enrolled provider, Swaminathan has provided services to 113 Medicare beneficiaries, totaling 198 services with total Medicare billing of $13,110. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Newark, NJ
- Active Since 07/05/2006
- Last Updated 02/03/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1275564411
Products in Payments
- CABENUVA (Biological) $7,719
- DOVATO (Drug) $6,660
- TROGARZO (Drug) $1,961
- Veklury (Drug) $1,890
- EGRIFTA (Drug) $103.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Newark
Dr. Jihad Slim, Md, MD
Infectious Disease — Payments: $2.2M
Infectious Disease $2.2M
Dr. Maria Szabela, Md, MD
Infectious Disease — Payments: $336,664
Infectious Disease $336,664
Sally Hodder, M.d, M.D
Infectious Disease — Payments: $93,382
Infectious Disease $93,382
Wanda Figueroa, M.d, M.D
Infectious Disease — Payments: $13,660
Infectious Disease $13,660
Alexander Stoler, M.d, M.D
Infectious Disease — Payments: $5,931
Infectious Disease $5,931
Dr. Wesley Emmons, M.d, M.D
Infectious Disease — Payments: $3,509
Infectious Disease $3,509